CompuGroup Medical (COP) Q4 2024 earnings summary

Executive summary

• 2024 was a year of transition with a new CEO, a focus on customer centricity, operational excellence, innovation, and strategic acquisitions including Pridok, Emento Apps, and CPS Concept.

• CVC Capital Partners became a key strategic partner, acquiring nearly 22% of shares, launching a voluntary public tender offer, and planning a delisting offer in Q2 2025.

• The company emphasized cloud and AI-based healthcare solutions, expanding its portfolio with products like CGM ONE and CGM STELLA.

• IT security was enhanced, evidenced by receiving the C5 attestation.

Significant events and developments

• Acquisitions of Pridok, Emento Apps, and CPS Concept expanded the product portfolio and strengthened market position in Northern Europe and France.

• CVC Capital Partners' investment agreement changed the shareholder structure: Gotthardt family 50.1%, CVC 21.85%, free float 24.32%, treasury shares 3.72%.

• Planned delisting offer and postponed annual general meeting to August 1, 2025.

Financial highlights

• FY 2024 revenues were €1,154m, down 3% year-over-year; organic revenue declined 2%.

• Recurring revenues grew by 5% to €854m, now representing 74% of total revenues.

• Adjusted EBITDA was €225 million, margin at 19%, down 15% year-over-year.

• Free cash flow was €66 million, exceeding revised guidance but below prior year.

• Adjusted EPS was €1.27, down from €2.06 in FY 2023, below guidance due to higher tax payments.

• Dividend proposal set at legal minimum of €0.05 per share, down from €1.00 last year.